MX2020003562A - Anticuerpo multiespecifico. - Google Patents
Anticuerpo multiespecifico.Info
- Publication number
- MX2020003562A MX2020003562A MX2020003562A MX2020003562A MX2020003562A MX 2020003562 A MX2020003562 A MX 2020003562A MX 2020003562 A MX2020003562 A MX 2020003562A MX 2020003562 A MX2020003562 A MX 2020003562A MX 2020003562 A MX2020003562 A MX 2020003562A
- Authority
- MX
- Mexico
- Prior art keywords
- multispecific antibody
- nucleic acid
- vector
- binding domain
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención tiene relación con un anticuerpo multiespecífico que comprende al menos un dominio de unión CD137 y al menos un dominio de unión a PDL1, y composiciones farmacéuticas y métodos de uso de las mismas. La presente invención tiene relación además con un ácido nucleico que codifica dicho anticuerpo multiespecífico, un vector que comprende dicho ácido nucleico, una célula huésped que comprende dicho ácido nucleico o dicho vector, y un método para producir dicho anticuerpo multiespecífico.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17195779.8A EP3470426A1 (en) | 2017-10-10 | 2017-10-10 | Multispecific antibody |
EP18150465 | 2018-01-05 | ||
EP18167093 | 2018-04-12 | ||
EP18180814 | 2018-06-29 | ||
PCT/EP2018/077509 WO2019072868A1 (en) | 2017-10-10 | 2018-10-09 | MULTISPECIFIC ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003562A true MX2020003562A (es) | 2020-10-01 |
Family
ID=63799025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003562A MX2020003562A (es) | 2017-10-10 | 2018-10-09 | Anticuerpo multiespecifico. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230192897A1 (es) |
EP (1) | EP3694873A1 (es) |
JP (1) | JP7442443B2 (es) |
KR (1) | KR20200063155A (es) |
CN (1) | CN111194323A (es) |
AU (1) | AU2018348429A1 (es) |
BR (1) | BR112020006999A2 (es) |
CA (1) | CA3075969A1 (es) |
CL (2) | CL2020000937A1 (es) |
CO (1) | CO2020003882A2 (es) |
IL (1) | IL273576A (es) |
MA (1) | MA50352A (es) |
MX (1) | MX2020003562A (es) |
SG (1) | SG11202002982YA (es) |
WO (1) | WO2019072868A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
CN111183159A (zh) * | 2017-10-10 | 2020-05-19 | 努玛治疗有限公司 | 靶向cd137的抗体及其使用方法 |
KR20200083574A (ko) * | 2017-11-13 | 2020-07-08 | 크레센도 바이오로직스 리미티드 | Cd137 및 psma에 결합하는 분자 |
WO2021013142A1 (zh) * | 2019-07-22 | 2021-01-28 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 |
CN114555638B (zh) | 2019-10-11 | 2023-08-22 | 南京维立志博生物科技有限公司 | 结合4-1bb的抗体及其用途 |
EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
WO2022136693A1 (en) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
WO2023001987A2 (en) | 2021-07-22 | 2023-01-26 | University Of Dundee | Therapeutic muteins |
EP4273162A1 (en) | 2022-05-06 | 2023-11-08 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
WO2023214047A1 (en) | 2022-05-06 | 2023-11-09 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
ATE337403T1 (de) | 1999-12-24 | 2006-09-15 | Genentech Inc | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
CA2490009A1 (en) | 2002-06-21 | 2003-12-31 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
PT1517921E (pt) | 2002-06-28 | 2006-09-29 | Domantis Ltd | Ligandos duplamente especificos com semi-vida no soro aumentada |
JP2006500921A (ja) | 2002-07-30 | 2006-01-12 | ブリストル−マイヤーズ スクイブ カンパニー | ヒト4−1bbに対するヒト化抗体 |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US20040119010A1 (en) | 2002-11-01 | 2004-06-24 | The Regents Of The University Of Colorado | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
CA2569240A1 (en) | 2004-06-01 | 2005-12-15 | Domantis Limited | Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin |
CN101128487B (zh) | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
JP5602625B2 (ja) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | 結合物質のディスプレイ |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
HUE033438T2 (en) | 2008-09-26 | 2017-11-28 | Ucb Biopharma Sprl | Biological products |
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
MX2012000765A (es) | 2009-07-16 | 2012-02-13 | Glaxo Group Ltd | Dominios variables sencillos de union de albumina anti-suero mejorados. |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
KR101527300B1 (ko) | 2010-09-09 | 2015-06-09 | 화이자 인코포레이티드 | 4-1bb 결합 분자 |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CA2967426A1 (en) * | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
CA2977257A1 (en) * | 2015-02-22 | 2016-08-25 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd137 |
SG11201707383PA (en) * | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
CN115057936A (zh) | 2015-06-15 | 2022-09-16 | 努玛治疗有限公司 | 异源二聚体多特异性抗体形式 |
WO2017102835A1 (en) * | 2015-12-14 | 2017-06-22 | Complix Nv | Binding molecule comprising an alphabody-polypeptide and an antibody |
CN108779176A (zh) * | 2016-01-11 | 2018-11-09 | 印希比股份有限公司 | 多价和多特异性41bb结合融合蛋白 |
EP3694879A1 (en) | 2017-10-10 | 2020-08-19 | Numab Therapeutics AG | Antibodies targeting pdl1 and methods of use thereof |
CN111183159A (zh) | 2017-10-10 | 2020-05-19 | 努玛治疗有限公司 | 靶向cd137的抗体及其使用方法 |
-
2018
- 2018-10-09 US US16/754,604 patent/US20230192897A1/en active Pending
- 2018-10-09 CA CA3075969A patent/CA3075969A1/en active Pending
- 2018-10-09 SG SG11202002982YA patent/SG11202002982YA/en unknown
- 2018-10-09 BR BR112020006999-0A patent/BR112020006999A2/pt unknown
- 2018-10-09 WO PCT/EP2018/077509 patent/WO2019072868A1/en unknown
- 2018-10-09 JP JP2020519761A patent/JP7442443B2/ja active Active
- 2018-10-09 EP EP18783483.3A patent/EP3694873A1/en active Pending
- 2018-10-09 MX MX2020003562A patent/MX2020003562A/es unknown
- 2018-10-09 AU AU2018348429A patent/AU2018348429A1/en active Pending
- 2018-10-09 KR KR1020207010048A patent/KR20200063155A/ko not_active Application Discontinuation
- 2018-10-09 MA MA050352A patent/MA50352A/fr unknown
- 2018-10-09 CN CN201880065327.3A patent/CN111194323A/zh active Pending
-
2020
- 2020-03-24 IL IL273576A patent/IL273576A/en unknown
- 2020-03-30 CO CONC2020/0003882A patent/CO2020003882A2/es unknown
- 2020-04-07 CL CL2020000937A patent/CL2020000937A1/es unknown
-
2021
- 2021-01-06 CL CL2021000028A patent/CL2021000028A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3075969A1 (en) | 2019-04-18 |
IL273576A (en) | 2020-05-31 |
CL2021000028A1 (es) | 2021-05-28 |
SG11202002982YA (en) | 2020-04-29 |
CL2020000937A1 (es) | 2020-09-25 |
CO2020003882A2 (es) | 2020-05-29 |
JP2021501744A (ja) | 2021-01-21 |
JP7442443B2 (ja) | 2024-03-04 |
WO2019072868A1 (en) | 2019-04-18 |
US20230192897A1 (en) | 2023-06-22 |
MA50352A (fr) | 2020-08-19 |
KR20200063155A (ko) | 2020-06-04 |
CN111194323A (zh) | 2020-05-22 |
AU2018348429A1 (en) | 2020-03-12 |
BR112020006999A2 (pt) | 2020-10-06 |
EP3694873A1 (en) | 2020-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020003882A2 (es) | Anticuerpo multiespecifico | |
CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
BR112018005164A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer | |
CL2021001179A1 (es) | Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). | |
BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
BR112018008051A2 (pt) | vacinas de ácido nucleico para vírus de varicella zoster (vzv) | |
BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
CR20190199A (es) | Anticuerpos anti-pd-1 y sus usos | |
CL2018000829A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112016020112A2 (pt) | anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica | |
BR112018007017A2 (pt) | polipeptídeos | |
CL2019001517A1 (es) | Anticuerpos y métodos de su utilización. | |
BR112016010706A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo | |
EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
UY37523A (es) | Anticuerpos anti-ox40 y sus usos | |
BR112018003326A2 (pt) | anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos | |
BR112016015958A2 (pt) | Drives de genes guiados pelo rna |